読み込み中
Exagen Inc. develops and commercializes diagnostic testing solutions, leveraging its proprietary cell-bound complement activation products (CB-CAPs) technology under the AVISE brand throughout the United States. The company's mission is to equip rheumatologists with advanced tools for the precise diagnosis, prognosis, and ongoing management of autoimmune and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its flagship product, AVISE CTD, aids in distinguishing between various connective tissue diseases (CTDs) and other conditions with overlapping symptoms in symptomatic patients. The company's product portfolio includes AVISE Lupus, which assesses complement system activation by measuring B-cell C4d and erythrocyte-bound C4d in blood. AVISE APS offers a comprehensive panel of autoantibody tests for the diagnosis and management of Antiphospholipid Syndrome (APS). For SLE patients, AVISE SLE Prognostic provides an autoantibody panel to evaluate the potential for kidney, brain, and cardiovascular complications. Additionally, AVISE Vasculitis AAV utilizes a testing panel of individual analytes to assist physicians in the assessment and monitoring of anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis, while AVISE Anti-CarP helps identify RA patients prone to severe disease, and AVISE PC4d measures platelet-bound C4d. Further offerings include AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, designed to monitor hydroxychloroquine levels. Exagen also holds a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to advance the development of novel patented biomarkers. Incorporated in 2002, the company was formerly known as Exagen Diagnostics, Inc. before rebranding to Exagen Inc. in January 2019. Its headquarters are located in Vista, California.
前日終値
$8.42
+$0.25 · +3.06%
日中の時刻はETです。市場データは遅延する場合があります。
Exagen Inc. develops and commercializes diagnostic testing solutions, leveraging its proprietary cell-bound complement activation products (CB-CAPs) technology under the AVISE brand throughout the United States. The company's mission is to equip rheumatologists with advanced tools for the precise diagnosis, prognosis, and ongoing management of autoimmune and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its flagship product, AVISE CTD, aids in distinguishing between various connective tissue diseases (CTDs) and other conditions with overlapping symptoms in symptomatic patients. The company's product portfolio includes AVISE Lupus, which assesses complement system activation by measuring B-cell C4d and erythrocyte-bound C4d in blood. AVISE APS offers a comprehensive panel of autoantibody tests for the diagnosis and management of Antiphospholipid Syndrome (APS). For SLE patients, AVISE SLE Prognostic provides an autoantibody panel to evaluate the potential for kidney, brain, and cardiovascular complications. Additionally, AVISE Vasculitis AAV utilizes a testing panel of individual analytes to assist physicians in the assessment and monitoring of anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis, while AVISE Anti-CarP helps identify RA patients prone to severe disease, and AVISE PC4d measures platelet-bound C4d. Further offerings include AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, designed to monitor hydroxychloroquine levels. Exagen also holds a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to advance the development of novel patented biomarkers. Incorporated in 2002, the company was formerly known as Exagen Diagnostics, Inc. before rebranding to Exagen Inc. in January 2019. Its headquarters are located in Vista, California.
日中レンジ
現在 $8.42
52週レンジ
現在 $8.42
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
72
割安
センチメント
58
まちまち
リスク
78
高リスク
モメンタム
31
弱含み
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Exagen Inc. develops and commercializes diagnostic testing solutions, leveraging its proprietary cell-bound complement activation products (CB-CAPs) technology under the AVISE brand throughout the United States. The company's mission is to equip rheumatologists with advanced tools for the precise diagnosis, prognosis, and ongoing management of autoimmune and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its flagship product, AVISE CTD, aids in distinguishing between various connective tissue diseases (CTDs) and other conditions with overlapping symptoms in symptomatic patients. The company's product portfolio includes AVISE Lupus, which assesses complement system activation by measuring B-cell C4d and erythrocyte-bound C4d in blood. AVISE APS offers a comprehensive panel of autoantibody tests for the diagnosis and management of Antiphospholipid Syndrome (APS). For SLE patients, AVISE SLE Prognostic provides an autoantibody panel to evaluate the potential for kidney, brain, and cardiovascular complications. Additionally, AVISE Vasculitis AAV utilizes a testing panel of individual analytes to assist physicians in the assessment and monitoring of anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis, while AVISE Anti-CarP helps identify RA patients prone to severe disease, and AVISE PC4d measures platelet-bound C4d. Further offerings include AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, designed to monitor hydroxychloroquine levels. Exagen also holds a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to advance the development of novel patented biomarkers. Incorporated in 2002, the company was formerly known as Exagen Diagnostics, Inc. before rebranding to Exagen Inc. in January 2019. Its headquarters are located in Vista, California.
日中レンジ
現在 $8.42
52週レンジ
現在 $8.42
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 6657.5万 USD | 5564.1万 USD | 5254.8万 USD | 4556.3万 USD | 4829.9万 USD |
| 売上原価 | 2777.6万 USD | 2252.9万 USD | 2309.2万 USD | 2421.4万 USD | 2058.8万 USD |
| 粗利益 | 3879.9万 USD | 3311.2万 USD | 2945.6万 USD | 2134.9万 USD | 2771.1万 USD |
| 研究開発 | 625.4万 USD | 537.5万 USD | 486.5万 USD | 987.6万 USD | 723.7万 USD |
| 販売・一般管理 | 4661.5万 USD | 4137.3万 USD | 4742.8万 USD | 5201.8万 USD | 4454.1万 USD |
| 営業費用 | 5286.9万 USD | 4674.8万 USD | 5229.3万 USD | 6740万 USD | 5177.8万 USD |
| 受取利息 | 28.9万 USD | 76.7万 USD | 151.6万 USD | 83万 USD | 1.6万 USD |
| 支払利息 | 431.8万 USD | 223.4万 USD | 233.5万 USD | 244.8万 USD | 262.5万 USD |
| 減価償却費と償却費 | 211.8万 USD | 172.4万 USD | 216.8万 USD | 155.7万 USD | 94.8万 USD |
| 営業利益 | −1407万 USD | −1363.6万 USD | −2283.7万 USD | −4605.1万 USD | −2406.7万 USD |
| 純利益 | −1995.1万 USD | −1511.5万 USD | −2368.9万 USD | −4738.7万 USD | −2685.1万 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$8.00
下落余地（4.99%）この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI304.5万0.00%2.3兆 USD0.03%$381.94+0.63%
Vanguard Extended Market ETFVXF139.82万0.00%954億 USD0.05%$235+0.80%
iShares Micro-Cap ETFIWC35.95万0.03%13.17億 USD0.60%$183+0.11%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM21万0.18%1.17億 USD0.73%$15.9402+0.25%
Invesco NASDAQ Future Gen 200 ETFQQQS13.76万0.60%2275.83万 USD0.20%$42.145+1.39%
Dimensional - US Core Equity 2 ETFDFAC5.32万0.00%885.96億 USD0.21%$45.33+0.49%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMInvesco NASDAQ Future Gen 200 ETFQQQSDimensional - US Core Equity 2 ETFDFACAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
